White Pine Capital LLC Sells 1,723 Shares of Kenvue Inc. (NYSE:KVUE)

White Pine Capital LLC decreased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 3.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 55,384 shares of the company’s stock after selling 1,723 shares during the quarter. White Pine Capital LLC’s holdings in Kenvue were worth $1,192,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. Clearstead Advisors LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue during the 4th quarter valued at about $27,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $28,000. Venturi Wealth Management LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $28,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE stock traded down $0.16 during trading hours on Friday, reaching $18.86. 15,454,689 shares of the company were exchanged, compared to its average volume of 13,458,618. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The stock’s fifty day moving average is $19.84 and its two-hundred day moving average is $20.13. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, equities analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Analyst Ratings Changes

Several brokerages have recently weighed in on KVUE. William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada reduced their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.